Patient Identification Platform Data Network Surpasses 14 Million Unique Patients Lives, Achieving Significant Growth Milestone

​​Patient identification Platform (Patient iP), an emerging health data network supplier to the pharmaceutical and CRO industries, today announced that the company’s Connected Site Network now represents more than 14 million unique patient records across 4,000 practice sites. This achievement comes only two years after the launch of the Platform for objective clinical trial matching, a solution hailed by Microsoft in 2016 as a Health Innovation Award winner.

The Patient iP Connected Site Network is comprised of longitudinal patient records across sites that range in size from solo-practitioners to larger multi-specialty groups. The data represents nearly every medical specialty with particular emphasis on the areas of gastroenterology, neurology, obstetrics/gynecology, urology and others. The data is wholly de-identified and can be made accessible for clinical research initiatives seeking to optimize protocol design, site selection and of course, patient recruitment.

“This is an important milestone and inflection point for our young company and also speaks to an essentially untapped market of mid/smaller sized medical groups that want to participate in clinical trials to provide additional treatment options to patients, while potentially recognizing new revenue streams for their groups,” offered Patient iP founder and CEO, Michael Margiotta.  “Used in concert, our Network along with our technology solution performs automated, and thus highly streamlined, matching of patients to trials based on eligibility criteria. This ensures that for sponsors and CROs, only sites with actual and appropriate subjects become activated,” he added.

The Patient iP technology can easily integrate with any EMR system capable of outputting CCDA records; all personal health information is removed using industry standard de-identification processes. The remaining data can be analyzed against a research study’s inclusion and exclusion criteria in a matter of minutes, creating unique patient cohorts that narrowly map to the patient universe required for a successful drug trial. This approach is practice-proven to drive value for the research entity due to better timeliness and the leverage of current EMR investments at the site, ultimately surfacing subjects for research that might otherwise have gone overlooked.

“News reports reflecting on the lack of heterogeneity in clinical trials are published nearly weekly. In fact, a recent FDA analysis found that only 25 percent of patients in cancer trials were 65 or older, yet more than 60% of cancer patients are older adults. With our synergistic data and technology approach, we believe we can help change the issue of under-representation in research which is only poised to intensify in nature as personalized medicine therapies only continue to expand,” said Margiotta.

About Patient identification Platform

The patented Patient iP solution bridges many of the most significant and costly gaps encountered when sponsors and contract research organizations conduct clinical trials: timely patient identification and enrollment. Adoption of the Platform enables CROs to streamline operations, helps study sites leverage existing electronic patient health data, and provides life sciences organizations with the speed necessary to achieve first-mover status. In concert, Patient iP's unique technology and expansive Connected Site Network allow for faster development and approval of drugs and therapies, benefiting patients as well given the potential for healthier and longer lives. For more information, visit us at or follow us on Twitter @PatientIP.

Source: Patient identification Platform